iHuman director reports option holdings in Form 3
iHuman Inc. director Li Xuenan reported existing option holdings in a Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
iHuman Inc. director Li Xuenan reported existing option holdings in a Form 3. The filing shows two option grants, each covering 27,000 underlying Class A ordinary shares at an exercise price of 0.0500 per share. One grant expires on November 30, 2030 and fully vested by October 8, 2023. The second grant expires on December 15, 2032 and vests in four equal annual installments after its December 15, 2022 grant date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
Footnotes (2)
- F1. These options were granted on November 30, 2020 and vested over a three-year period, with 33.33% of the options vesting on October 8, 2021, 33.33% on October 8, 2022, and the remaining 33.34% on October 8, 2023.
- F2. These options were granted on December 15, 2022 and vest in equal installments over a four-year period, with 25% of the options vest on each anniversary after the grant date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does iHuman Inc. (IH) director Li Xuenan report in this Form 3?
What are the exercise price and expiration dates of Li Xuenan’s iHuman (IH) options?
How do the iHuman Inc. (IH) options held by Li Xuenan vest over time?
Does this iHuman (IH) Form 3 show any insider buying or selling activity?
AI-generated analysis. How Rhea-AI works. Not financial advice.